Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Umeclidinium/Vilanterol in COPD
NCT01636713Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jul 2012; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01636713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636713.